TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Clinical trial NCT04888546 · UNKNOWN

Trial details

NCT number: NCT04888546
Sponsor: Chinese Academy of Medical Sciences
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

Start date: 2021-04-30
Primary completion: 2024-07-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.